Robert Yarchoan, M.D.
HIV and AIDS Malignancy Branch
Head, Retroviral Disease Section Branch Chief
National Cancer Institute
9000 Rockville Pike
Building 10, Room 10S255
Bethesda, MD 20892
Phone: 301-496-0328
Fax: 301-480-5955
ryln@nih.gov
Dr. Yarchoan received his B.A. from Amherst College with a major in biophysics and his M.D. from the University of Pennsylvania. He trained in internal medicine at the University of Minnesota and immunology in the Metabolism Branch, NCI. He then joined the laboratory of Dr. Samuel Broder, where he played a major role in the development of the first effective therapies for HIV infection, including zidovudine (AZT), didanosine (ddI), and zalcitabine (ddC). In particular, he led the first clinical trials of these drugs, was a co-inventor of didanosine and zalcitabine as AIDS therapies, and led initial studies of combination anti-HIV therapy. He was section chief in the Medicine Branch from 1991 to 1996 and was named chief of the newly formed HIV and AIDS Malignancy Branch in 1996. Since that time, he has focused much of his research on AIDS-related malignancies. Among other honors, he has been awarded the Assistant Secretary for Health Award and the U.S. Public Health Service Outstanding Service Medal, has been inducted as a Fellow of the American Association for the Advancement of Science, and is a member of the American Society for Clinical Investigation.
Dr. Yarchoan's Clinical Trials:
NCI is currently conducting the following trials for patients with HIV/AIDS-related cancers. Click on the trials below for additional details, including a summary of eligibility criteria, treatment plan, and information on how to contact the study team directly.
Back to Top
